Zenas BioPharma

Company snapshot

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zenas BioPharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Zenas BioPharma.

1. Jun 8, 2026 Clinical update

   ZB012-02-002 — Phase 2

2. Jun 8, 2026 Clinical update

   ZB020-03-001 — Phase 3

3. Jun 8, 2026 Clinical update

   ZB012-02-001 — Phase 2

4. Jun 8, 2026 Clinical update

   Orelabrutinib — Phase 3

5. Jun 8, 2026 Clinical update

   Orelabrutinib — Phase 3

View all clinical trial activity →

• What is Zenas BioPharma?

  Zenas BioPharma is a biotech organization headquartered in Waltham, USA. It trades on NYSE under ticker ZBIO. Primary therapeutic focus areas include Systemic Lupus Erythematosus, Primary Progressive Multiple Sclerosis (PPMS), RELAPSING MULTIPLE SCLEROSIS, IgG4 Related Disease, R

• Is Zenas BioPharma publicly traded?

  Yes. Zenas BioPharma is listed with ticker ZBIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Zenas BioPharma develop or market?

  We link 10 drug profile(s) where Zenas BioPharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zenas-biopharma#company-drugs.

• What are the latest developments for Zenas BioPharma?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zenas BioPharma focus on?

  Zenas BioPharma focuses on Systemic Lupus Erythematosus, Primary Progressive Multiple Sclerosis (PPMS), RELAPSING MULTIPLE SCLEROSIS based on our analysis of their pipeline programs and drug development activities.